NEW YORK, July 12 - Cellomics, the Pittsburgh, PA-based maker of integrated informatics and cell-screening technologies, has acquired Momentum Healthcare, a developer of drug discovery software, the company said Thursday.
Terms of the deal, which was formalized today but has been under negotiation for some time, were not disclosed and a company official declined to comment immediately.
Ian Shaw, the CEO of Momentum, has relocated from the company's headquarters in Southampton and Cardiff, UK, to Pittsburgh to take the position as vice president of therapeutic discovery for Cellomics. Mark Collins of Momentum has also moved to the US to become Cellomics' senior director of pharmaceutical informatics.
This merger comes eight months after Cellomics postponed its initial public offering.